Optimize Sample Selections For Study Cohorts With Discovery’s Immunophenotypic Characterization of Disease BMMCs.
CHARACTERIZATIONS OF DISEASE BMMCS
- Multiparametric immunophenotyping by flow cytometry tailored to the specific disease indication. For more information see Technical Data Sheets for AML and MM specific panels.
- HLA Typing: Diseased BMMCs are typed for HLA-A02 via flow cytometry.
- Patient Demographics: Age, sex, ethnicity, weight, height, smoking status, and alcohol history are available for diseased BMMCs samples.
- Pathology Report: Confirmation of diagnosis, donor demographic data, date of procedure, and if applicable, current and previous treatments, stage, grade, comorbidities, current medications, and lab values.
Bone Marrow Mononuclear Cells Product Details
Disease BMMCs
- Composed of both normal and malignant cells
- Immunophenotypes of malignant cells are readily identified by flow cytometry
- Isolated via density gradient centrifugation
- Cryopreserved in 90% heat-inactivated FBS +10% DMSO and use sodium heparin as an anticoagulant
- Cell counts and viability are determined using AOPI staining on a Nexcelom Cellometer
Normal BMMCs
- Collected via elective bone marrow aspirates from fully consented healthy donors following IRB approved protocols
- Isolated via density gradient centrifugation
- Cryopreserved in 90% heat-inactivated FBS +10% DMSO and use sodium heparin as an anticoagulant
- Cell counts and viability are determined using AOPI staining on a Nexcelom Cellometer
BMMC Matched Sets
Our Discovery Partners® network allows for large-scale, prospective collections of high-quality matched sample sets of human biospecimens.
Each matched sample set is provided with the base clinical data from the patient case, along with redacted pathology information.
BMMCs Technical Resources
AML BMMC Technical Data Sheet
Product information for acute myeloid leukemia BMMCs characterized by flow cytometry.
MM BMMC Technical Data Sheet
Product information for multiple myeloma BMMCs characterized by flow cytometry.
Protocols
Standard processing of diseased bone marrow mononuclear cells (BMMCs).
Need Biomarker Characterization For Your BMMCs?
While our biospecimens are highly characterized, we also provide streamlined multi-omic biomarker analyses to further characterize biospecimens from our inventory or from your studies via our global CLIA / CAP service laboratories*.
Genomics
- HudsonAlpha Discovery
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeting Panels
- Hi-Fi Long Read Sequencing
- RNA Sequencing
- Single Cell Sequencing
Pathology
- IHC
- Multiplexed IF (mIF)
- RNA Scope
- Digital Pathology & Image Analysis
- PCR
- In-Situ Hybridization
- Colorimetric
Cell Biology
- Flow Cytometry
- Dissociation & Isolation
- Cell Culture & Expansion
Proteomics
- Proteogenomics
- Mass Spectrometry
- Multiplexed Immunoassays
*HudsonAlpha Discovery Sequencing and Bioinformatics laboratory is CLIA registered, pending CAP accreditation.
Learn More
Frequently Asked Questions
How are the cell counts and viabilities of BMMCs determined?
Cell counts and viability are determined using AOPI staining on a Nexcelom Cellometer.
How is post-thaw cell count and viability performed?
What are the recommended storage conditions for the cryopreserved BMMCs?
How are Blast percentages determined?
How are BMMCs processed?
- You can find our protocols by clicking the links below:
- We also have the ability to follow our clients' custom processing protocols and help them develop new processing protocols based on their needs.
Are blast percentages available for diseased PBMC and BMMC samples?
To propel your projects with The Power of Discovery.™
Contact Us Today
Let us know about your project!
